EGFR and non-small cell lung carcinoma: The meta-analysis demonstrated (Figure 7) that PD-L1/PD-1 inhibitors in conjunction with chemotherapy vs. chemotherapy significantly improved the PFS of NSCLC patients with EGFR mutations (HR, 0.63; 95% CI, (0.42, 0.94)).